MX2021012398A - Metodos de terapia antitumoral. - Google Patents

Metodos de terapia antitumoral.

Info

Publication number
MX2021012398A
MX2021012398A MX2021012398A MX2021012398A MX2021012398A MX 2021012398 A MX2021012398 A MX 2021012398A MX 2021012398 A MX2021012398 A MX 2021012398A MX 2021012398 A MX2021012398 A MX 2021012398A MX 2021012398 A MX2021012398 A MX 2021012398A
Authority
MX
Mexico
Prior art keywords
methods
tumor therapy
antagonist
subject
effective dose
Prior art date
Application number
MX2021012398A
Other languages
English (en)
Inventor
Itzhak Mendel
Niva Yacov
Eyal Breitbart
Minei Tamar Rachmilewitz
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of MX2021012398A publication Critical patent/MX2021012398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La divulgación proporciona métodos para tratar un tumor en un sujeto que lo necesita, que comprenden administrar al sujeto la combinación de una dosis efectiva de un vector que comprende un gen quimera Fas enlazado operativamente a un promotor específico de células endoteliales y una dosis efectiva de un inhibidor de punto de control inmunitario. En algunos aspectos de la divulgación, el inhibidor de punto de control inmunitario es un antagonista de PD-1 o un antagonista de PD-L1.
MX2021012398A 2019-04-12 2020-04-13 Metodos de terapia antitumoral. MX2021012398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833402P 2019-04-12 2019-04-12
PCT/IB2020/053477 WO2020208612A1 (en) 2019-04-12 2020-04-13 Methods of anti-tumor therapy

Publications (1)

Publication Number Publication Date
MX2021012398A true MX2021012398A (es) 2021-11-12

Family

ID=70333996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012398A MX2021012398A (es) 2019-04-12 2020-04-13 Metodos de terapia antitumoral.

Country Status (13)

Country Link
US (1) US20220185891A1 (es)
EP (1) EP3952903A1 (es)
JP (1) JP2022528425A (es)
KR (1) KR20210152504A (es)
CN (1) CN113710265A (es)
AU (1) AU2020271998A1 (es)
BR (1) BR112021020225A2 (es)
CA (1) CA3134080A1 (es)
EA (1) EA202192800A1 (es)
IL (1) IL287135A (es)
MX (1) MX2021012398A (es)
SG (1) SG11202109441UA (es)
WO (1) WO2020208612A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245249A1 (en) * 2022-06-22 2023-12-28 Race Oncology Ltd Treatment of melanoma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
JP6196040B2 (ja) 2010-01-05 2017-09-13 バスキュラー バイオジェニックス リミテッド 特異的な抗血管形成アデノウイルス剤の使用法
SG10201500048SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
CN103261298B (zh) 2010-10-18 2014-07-16 道达尔研究技术弗吕公司 能膨胀的乙烯基芳族聚合物
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
SG11201502941VA (en) * 2012-10-17 2015-05-28 Vascular Biogenics Ltd Treatment methods using adenovirus
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3161003A2 (en) * 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
US20190185571A1 (en) * 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors

Also Published As

Publication number Publication date
CN113710265A (zh) 2021-11-26
AU2020271998A1 (en) 2021-09-30
JP2022528425A (ja) 2022-06-10
US20220185891A1 (en) 2022-06-16
BR112021020225A2 (pt) 2021-12-07
IL287135A (en) 2021-12-01
EA202192800A1 (ru) 2022-03-30
EP3952903A1 (en) 2022-02-16
KR20210152504A (ko) 2021-12-15
CA3134080A1 (en) 2020-10-15
SG11202109441UA (en) 2021-09-29
WO2020208612A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
MX2017003227A (es) Terapias de combinacion de inhibidores de alk.
MX2019012032A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
ZA201906001B (en) Combination therapy for the treatment or prevention of tumours
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
PH12016500841A1 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
MX2019000286A (es) Una combinación farmacéutica y método para la regulación del microentorno tumoral e inmunoterapia.
MY185579A (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
AR116121A1 (es) Métodos de tratamiento del cáncer
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
MX2019013862A (es) Terapia de combinacion.
WO2020092792A3 (en) Method of enhancing immune-based therapy
MX2022004577A (es) Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
NZ712691A (en) C. novyi for the treatment of solid tumors in humans
IL290123A (en) Combined treatment including antibodies against claudin 18.2 and immune checkpoint inhibitors for cancer treatment
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
PH12018502381A1 (en) Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer